New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies

Autor:	Anna Lochocka, Mario Berli, Cesar Gonzalo Calvo Vargas, Christelle Foucher, Petr Reichert, Axel Schaeffer, Hans-Friedrich Koch, Patrick Aubonnet, Dmitry Belenky
Rok vydání:	2015
Předmět:	Male Simvastatin medicine.medical_specialty Time Factors Statin Apolipoprotein B medicine.drug_class Fixed-dose combination Pharmacology Gastroenterology Double-Blind Method Fenofibrate Internal medicine medicine Humans Pharmacology (medical) Cystatin C Triglycerides Aged Dyslipidemias biology medicine.diagnostic_test business.industry Cholesterol HDL C-reactive protein nutritional and metabolic diseases General Medicine Middle Aged medicine.disease Drug Combinations C-Reactive Protein Treatment Outcome biology.protein Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Lipid profile Biomarkers Dyslipidemia medicine.drug
Zdroj:	Cardiovascular Therapeutics. 33:329-337
ISSN:	1755-5914
DOI:	10.1111/1755-5922.12148
Popis:	SummaryAims Guidelines propose additional therapy to statin to treat elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDLC) in dyslipidemic patients. We evaluated the effects of new fixed-dose combinations (FDC) of fenofibrate/simvastatin on plasma lipids versus simvastatin or fenofibrate monotherapies. Methods Subjects with mixed dyslipidemia at high or very high cardiovascular risk on stable statin therapy for at least 3 months were included in a randomized, double-blind, active-control, parallel-group study. Patients were treated with FDC fenofibrate/simvastatin 145/20 mg or 145/40 mg, simvastatin 20 mg or 40 mg, or fenofibrate 145 mg for 12 weeks. Plasma lipids, C-reactive protein, and cystatin C were measured before and after treatments. Differences in % changes were compared between FDC fenofibrate/simvastatin and monotherapies. Results Significant differences between FDC fenofibrate/simvastatin and simvastatin monotherapies were observed for the % change of TG (LS mean difference [two-sided 95% CI]: −32.2% [−38.6%, −25.8%], P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2629503c4ff98b4cecf4ae29e190fcd9 https://doi.org/10.1111/1755-5922.12148 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.